Current Hematologic Malignancy Reports

, Volume 12, Issue 5, pp 432–441 | Cite as

Recent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia

  • Kim-Hien T. DaoEmail author
  • Jeffrey W. Tyner
  • Jason Gotlib
Myeloproliferative Neoplasms (B Stein, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Myeloproliferative Neoplasms


Purpose of Review

We reviewed recent diagnostic and therapeutic progress in chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML). We summarized recent genetic data that may guide future efforts towards implementing risk-adapted therapy based on mutational profile and improving disease control and survival of affected patients.

Recent Findings

Recent genetic data in CNL and aCML prompted modifications to the World Health Organization (WHO) diagnostic criteria, which have improved our understanding of how CNL and aCML are different diseases despite sharing common findings of peripheral granulocytosis and marrow myeloid hyperplasia. The overlap of recurrently mutated genes between aCML and CMML support considering CSF3R-T618I mutated cases as a distinct entity, either as CNL or CNL with dysplasia. Ongoing preclinical and clinical studies will help to further inform the therapeutic approach to these diseases.


Our understanding of CNL and aCML has greatly advanced over the last few years. This will improve clarity for the diagnosis of these diseases, provide a strategy for risk stratification, and guide risk-adapted therapy.


Chronic neutrophilic leukemia Atypical chronic myelogenous leukemia Colony-stimulating factor 3 receptor (CSF3R) JAK-STAT signaling Myelodysplasia/myeloproliferative neoplasm (MDS/MPN) 



K.T.D. is supported by the Knight Cancer Institute. J.W.T. is supported by the Leukemia & Lymphoma Society, the V Foundation for Cancer Research, Gabrielle’s Angel Foundation for Cancer Research, and the National Cancer Institute (5R00CA151457-04; 1R01CA183947-01). J.G. is supported by the Charles and Ann Johnson Foundation.

Compliance with Ethical Standards

Conflict of Interest

All authors on this manuscript are investigators of the NCT02092324 clinical trial evaluating the safety and efficacy of ruxolitinib (Incyte Corporation) in patients with aCML and CNL. Incyte is providing financial support of this trial. The authors do not perceive any conflict of interest in their presentation of data and preparation of this manuscript. K.T.D. and J.G. additionally serve on advisory board activities sponsored by Incyte and receive honoraria in support of their participation.


Jeffrey W. Tyner reports grants from Agios, Aptose, Array, AstraZeneca, Constellation, Genentech, Incyte, Janssen, Seattle Genetics, Syros, Takeda, and other from Leap Oncology outside the submitted work.

Kim-Hien T. Dao and Jason R. Gotlib reports grants and other from Incyte Corporation outside the submitted work.

Human and Animal Rights and Informed Consent

This article contains no studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    •• Elliott MA, Tefferi A. Chronic neutrophilic leukemia 2016: update on diagnosis, molecular genetics, prognosis, and management. Am J Hematol. 2016;91(3):341–9. Summary of expected changes to WHO CNL and aCML diagnostic criteria CrossRefPubMedGoogle Scholar
  2. 2.
    •• Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–405. Summary of expected changes to WHO CNL and aCML diagnostic criteria CrossRefPubMedGoogle Scholar
  3. 3.
    Mc Lornan DP, Percy MJ, Jones AV, Cross NC, Mc Mullin MF. Chronic neutrophilic leukemia with an associated V617F JAK2 tyrosine kinase mutation. Haematologica. 2005;90(12):1696–7.PubMedGoogle Scholar
  4. 4.
    Lea NC, Lim Z, Westwood NB, Arno MJ, Gaken J, Mohamedali A, et al. Presence of JAK2 V617F tyrosine kinase mutation as a myeloid-lineage-specific mutation in chronic neutrophilic leukaemia. Leukemia. 2006;20(7):1324–6.CrossRefPubMedGoogle Scholar
  5. 5.
    Kako S, Kanda Y, Sato T, Goyama S, Noda N, Shoda E, et al. Early relapse of JAK2 V617F-positive chronic neutrophilic leukemia with central nervous system infiltration after unrelated bone marrow transplantation. Am J Hematol. 2007;82(5):386–90.CrossRefPubMedGoogle Scholar
  6. 6.
    Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and myelodysplastic syndromes. Blood. 2005;106(4):1207–9.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Gajendra S, Gupta R, Chandgothia M, Kumar L, Gupta R, Chavan SM. Chronic neutrophilic leukemia with V617F JAK2 mutation. Indian Journal of Hematology & Blood Transfusion : An Official Journal of Indian Society of Hematology and Blood Transfusion. 2014;30(2):139–42.CrossRefGoogle Scholar
  8. 8.
    Cui Y, Li B, Gale RP, Jiang Q, Xu Z, Qin T, et al. CSF3R, SETBP1 and CALR mutations in chronic neutrophilic leukemia. J Hematol Oncol. 2014;7:77.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Gotlib J, Maxson JE, George TI, Tyner JW. The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment. Blood. 2013;122(10):1707–11.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    •• Gambacorti-Passerini CB, Donadoni C, Parmiani A, Pirola A, Redaelli S, Signore G, et al. Recurrent ETNK1 mutations in atypical chronic myeloid leukemia. Blood. 2015;125(3):499–503. First report of recurrent ETNK1 mutations in aCML CrossRefPubMedGoogle Scholar
  11. 11.
    Kosmider O. Mutations of ETNK1 in aCML and CMML. Blood. 2015;125(3):422–3.CrossRefPubMedGoogle Scholar
  12. 12.
    Lasho TL, Finke CM, Zblewski D, Patnaik M, Ketterling RP, Chen D, et al. Novel recurrent mutations in ethanolamine kinase 1 (ETNK1) gene in systemic mastocytosis with eosinophilia and chronic myelomonocytic leukemia. Blood cancer journal. 2015;5:e275.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Elliott MA, Hanson CA, Dewald GW, Smoley SA, Lasho TL, Tefferi A. WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature. Leukemia. 2005;19(2):313–7.CrossRefPubMedGoogle Scholar
  14. 14.
    Breccia M, Biondo F, Latagliata R, Carmosino I, Mandelli F, Alimena G. Identification of risk factors in atypical chronic myeloid leukemia. Haematologica. 2006;91(11):1566–8.PubMedGoogle Scholar
  15. 15.
    Stein BL, Tiu RV. Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms. Journal of Interferon & Cytokine Research: The Official Journal of the International Society for Interferon and Cytokine Research. 2013;33(4):145–53.CrossRefGoogle Scholar
  16. 16.
    Hasselbalch HC. A new era for IFN-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Expert Rev Hematol. 2011;4(6):637–55.CrossRefPubMedGoogle Scholar
  17. 17.
    Meyer S, Feremans W, Cantiniaux B, Capel P, Huygen K, Dicato M. Successful alpha-2b-interferon therapy for chronic neutrophilic leukemia. Am J Hematol. 1993;43(4):307–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Bohm J, Schaefer HE. Chronic neutrophilic leukaemia: 14 new cases of an uncommon myeloproliferative disease. J Clin Pathol. 2002;55(11):862–4.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Zhang X, Pan J, Guo J. Presence of the JAK2 V617F mutation in a patient with chronic neutrophilic leukemia and effective response to interferon alpha-2b. Acta Haematol. 2013;130(1):44–6.CrossRefPubMedGoogle Scholar
  20. 20.
    Yassin MA, Kohla S, Al-Sabbagh A, Soliman AT, Yousif A, Moustafa A, et al. A case of chronic neutrophilic leukemia successfully treated with pegylated interferon alpha-2a. Clinical Medicine Insights Case Reports. 2015;8:33–6.PubMedPubMedCentralGoogle Scholar
  21. 21.
    Choi IK, Kim BS, Lee KA, Ryu S, Seo HY, Sul H, et al. Efficacy of imatinib mesylate (STI571) in chronic neutrophilic leukemia with t(15;19): case report. Am J Hematol. 2004;77(4):366–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Shi J, Ni Y, Li J, Qiu H, Miao K. Concurrent chronic neutrophilic leukemia blast crisis and multiple myeloma: a case report and literature review. Oncol Lett. 2015;9(5):2208–10.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Jiang H, Wu Z, Ren LI, Tao D, Tong H. Decitabine for the treatment of atypical chronic myeloid leukemia: a report of two cases. Oncol Lett. 2016;11(1):689–92.PubMedGoogle Scholar
  24. 24.
    Tong X, Li J, Zhou Z, Zheng D, Liu J, Su C. Efficacy and side-effects of decitabine in treatment of atypical chronic myeloid leukemia. Leukemia & Lymphoma. 2015;56(6):1911–3.CrossRefGoogle Scholar
  25. 25.
    •• Maxson JE, Gotlib J, Pollyea DA, Fleischman AG, Agarwal A, Eide CA, et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med. 2013;368(19):1781–90. CSF3R -T618I first reported as a common oncogenic driver in CNL and some aCML CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Dao KH, Solti MB, Maxson JE, Winton EF, Press RD, Druker BJ, et al. Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia. Leukemia Research Reports. 2014;3(2):67–9.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Lasho TL, Mims A, Elliott MA, Finke C, Pardanani A, Tefferi A. Chronic neutrophilic leukemia with concurrent CSF3R and SETBP1 mutations: single colony clonality studies, in vitro sensitivity to JAK inhibitors and lack of treatment response to ruxolitinib. Leukemia. 2014;28(6):1363–5.CrossRefPubMedGoogle Scholar
  28. 28.
    Ammatuna E, Eefting M, van Lom K, Kavelaars FG, Valk PJ, Touw IP. Atypical chronic myeloid leukemia with concomitant CSF3R T618I and SETBP1 mutations unresponsive to the JAK inhibitor ruxolitinib. Ann Hematol. 2015;94(5):879–80.CrossRefPubMedGoogle Scholar
  29. 29.
    Nooruddin Z, Miltgen N, Wei Q, Schowinsky J, Pan Z, Tobin J, et al. Changes in allele frequencies of CSF3R and SETBP1 mutations and evidence of clonal evolution in a chronic neutrophilic leukemia patient treated with ruxolitinib. Haematologica. 2017;102(5):e207–e9.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Stahl M, Xu ML, Steensma DP, Rampal R, Much M, Zeidan AM. Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia. Ann Hematol. 2016;95(7):1197–200.CrossRefPubMedGoogle Scholar
  31. 31.
    Gunawan AS, McLornan DP, Wilkins B, Waghorn K, Hoade Y, Cross NCP, et al. Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia. Haematologica. 2017;102(6):e238–e40.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Khanna V, Pierce ST, Dao KH, Tognon CE, Hunt DE, Junio B, et al. Durable disease control with MEK inhibition in a patient with NRAS-mutated atypical chronic myeloid leukemia. Cureus. 2015;7(12):e414.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Fu Y, Schroeder T, Zabelina T, Badbaran A, Bacher U, Kobbe G, et al. Postallogeneic monitoring with molecular markers detected by pretransplant next-generation or Sanger sequencing predicts clinical relapse in patients with myelodysplastic/myeloproliferative neoplasms. Eur J Haematol. 2014;92(3):189–94.CrossRefPubMedGoogle Scholar
  34. 34.
    Lim SN, Lee JH, Lee JH, Kim DY, Kim SD, Kang YA, et al. Allogeneic hematopoietic cell transplantation in adult patients with myelodysplastic/myeloproliferative neoplasms. Blood Research. 2013;48(3):178–84.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    •• Koldehoff M, Beelen DW, Trenschel R, Steckel NK, Peceny R, Ditschkowski M, et al. Outcome of hematopoietic stem cell transplantation in patients with atypical chronic myeloid leukemia. Bone Marrow Transplant. 2004;34(12):1047–50. Only case series documenting outcomes after allogeneic stem cell transplantation in aCML CrossRefPubMedGoogle Scholar
  36. 36.
    •• Pardanani A, Lasho TL, Laborde RR, Elliott M, Hanson CA, Knudson RA, et al. CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. Leukemia. 2013;27(9):1870–3. CSF3R -T618I reported as a highly specific oncogenic driver in CNL CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    • Meggendorfer M, Haferlach T, Alpermann T, Jeromin S, Haferlach C, Kern W, et al. Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia. Haematologica. 2014;99(12):e244–6. Compares specific mutations in CNL, aCML, and CMML CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    • Wang SA, Hasserjian RP, Fox PS, Rogers HJ, Geyer JT, Chabot-Richards D, et al. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood. 2014;123(17):2645–51. Describes distinct features between aCML and MDS/MPN unclassifiable in a large data set CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Dao KH, Tyner JW. What’s different about atypical CML and chronic neutrophilic leukemia? Hematology American Society of Hematology Education Program. 2015;2015:264–71.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Dincol G, Nalcaci M, Dogan O, Aktan M, Kucukkaya R, Agan M, et al. Coexistence of chronic neutrophilic leukemia with multiple myeloma. Leukemia & Lymphoma. 2002;43(3):649–51.CrossRefGoogle Scholar
  41. 41.
    Standen GR, Jasani B, Wagstaff M, Wardrop CA. Chronic neutrophilic leukemia and multiple myeloma. An association with lambda light chain expression. Cancer. 1990;66(1):162–6.CrossRefPubMedGoogle Scholar
  42. 42.
    Standen GR, Steers FJ, Jones L. Clonality of chronic neutrophilic leukaemia associated with myeloma: analysis using the X-linked probe M27 beta. J Clin Pathol. 1993;46(4):297–8.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Stevens B, Maxson J, Tyner J, Smith CA, Gutman JA, Robinson W, et al. Clonality of neutrophilia associated with plasma cell neoplasms: report of a SETBP1 mutation and analysis of a single institution series. Leukemia & Lymphoma. 2016;57(4):927–34.CrossRefGoogle Scholar
  44. 44.
    Tursz T, Flandrin G, Brouet JC, Seligmann M. Coexistence of a myeloma and a granulocytic leukemia in the absence of any treatment. Study of 4 cases. Nouv Rev Fr Hematol. 1974;14(6):693–704.PubMedGoogle Scholar
  45. 45.
    Deininger MWN, Tyner JW, Solary E. Turning the tide in myelodysplastic/myeloproliferative neoplasms. Nat Rev Cancer. 2017;17(7):425–40.CrossRefPubMedGoogle Scholar
  46. 46.
    Cui YJ, Jiang Q, Liu JQ, Li B, Xu ZF, Qin TJ, et al. The clinical characteristics, gene mutations and prognosis of chronic neutrophilic leukemia. Zhonghua xueyexue zazhi. 2017;38(1):28–32.PubMedGoogle Scholar
  47. 47.
    • Elliott MA, Pardanani A, Hanson CA, Lasho TL, Finke CM, Belachew AA, et al. ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia. Am J Hematol. 2015;90(7):653–6. ASXL1 mutations and impact on prognosis in CNL CrossRefPubMedGoogle Scholar
  48. 48.
    • Meggendorfer M, Bacher U, Alpermann T, Haferlach C, Kern W, Gambacorti-Passerini C, et al. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations. Leukemia. 2013;27(9):1852–60. Survey of SETBP1 mutations among aCML and MDS/MPN subtypes CrossRefPubMedGoogle Scholar
  49. 49.
    Maxson JE, Tyner JW. Genomics of chronic neutrophilic leukemia. Blood. 2017;129(6):715–22.CrossRefPubMedGoogle Scholar
  50. 50.
    Patnaik MM, Barraco D, Lasho TL, Finke CM, Reichard K, Hoversten KP, et al. Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia. Am J Hematol. 2017;92(6):542-48.
  51. 51.
    Tefferi A, Elliott M, Pardanani A. Chronic neutrophilic leukemia: novel mutations and their impact on clinical practice. Curr Opin Hematol. 2015;22(2):171–6.CrossRefPubMedGoogle Scholar
  52. 52.
    •• Piazza R, Valletta S, Winkelmann N, Redaelli S, Spinelli R, Pirola A, et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet. 2013;45(1):18–24. First report of recurrent SETBP1 mutations in aCML CrossRefPubMedGoogle Scholar
  53. 53.
    Muramatsu H, Makishima H, Maciejewski JP. Chronic myelomonocytic leukemia and atypical chronic myeloid leukemia: novel pathogenetic lesions. Semin Oncol. 2012;39(1):67–73.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    • Mason CC, Khorashad JS, Tantravahi SK, Kelley TW, Zabriskie MS, Yan D, et al. Age-related mutations and chronic myelomonocytic leukemia. Leukemia. 2016;30(4):906–13. Survey of mutations observed in CMML CrossRefPubMedGoogle Scholar
  55. 55.
    •• Fleischman AG, Maxson JE, Luty SB, Agarwal A, Royer LR, Abel ML, et al. The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition. Blood. 2013;122(22):3628–31. Animal model confirming CSF3R -T618I mutation is oncogenic CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    •• Maxson JE, Luty SB, MacManiman JD, Paik JC, Gotlib J, Greenberg P, et al. The Colony-stimulating factor 3 receptor T640N mutation is oncogenic, sensitive to JAK inhibition, and mimics T618I. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 2016;22(3):757–64. Animal model confirming CSF3R -T640N mutation is oncogenic CrossRefGoogle Scholar
  57. 57.
    Maxson JE, Luty SB, MacManiman JD, Abel ML, Druker BJ, Tyner JW. Ligand independence of the T618I mutation in the colony-stimulating factor 3 receptor (CSF3R) protein results from loss of O-linked glycosylation and increased receptor dimerization. J Biol Chem. 2014;289(9):5820–7.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Plo I, Zhang Y, Le Couedic JP, Nakatake M, Boulet JM, Itaya M, et al. An activating mutation in the CSF3R gene induces a hereditary chronic neutrophilia. J Exp Med. 2009;206(8):1701–7.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Zhang H, Means S, Schultz AR, Watanabe-Smith K, Medeiros BC, Bottomly D, et al. Unpaired extracellular cysteine mutations of CSF3R mediate gain or loss of function. Cancer Res. 2017;77(16):4258-67.
  60. 60.
    Dong F, Qiu Y, Yi T, Touw IP, Larner AC. The carboxyl terminus of the granulocyte colony-stimulating factor receptor, truncated in patients with severe congenital neutropenia/acute myeloid leukemia, is required for SH2-containing phosphatase-1 suppression of Stat activation. Journal of Immunology (Baltimore, Md: 1950). 2001;167(11):6447–52.CrossRefGoogle Scholar
  61. 61.
    van de Geijn GJ, Gits J, Aarts LH, Heijmans-Antonissen C, Touw IP. G-CSF receptor truncations found in SCN/AML relieve SOCS3-controlled inhibition of STAT5 but leave suppression of STAT3 intact. Blood. 2004;104(3):667–74.CrossRefPubMedGoogle Scholar
  62. 62.
    Kunter G, Woloszynek JR, Link DC. A truncation mutant of Csf3r cooperates with PML-RARalpha to induce acute myeloid leukemia in mice. Exp Hematol. 2011;39(12):1136–43.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    •• Rohrabaugh S, Kesarwani M, Kincaid Z, Huber E, Leddonne J, Siddiqui Z, et al. Enhanced MAPK signaling is essential for CSF3R-induced leukemia. Leukemia. 2017;31(8):1770-78. MAPK signaling is involved in the pathogenesis of membrane-proximal CSF3R mutations.
  64. 64.
    • Shou LH, Cao D, Dong XH, Fang Q, Wu Y, Zhang Y, et al. Prognostic significance of SETBP1 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia, and chronic neutrophilic leukemia: a meta-analysis. PLoS One. 2017;12(2):e0171608. Meta-analysis of SETBP1 mutations and impact on prognosis CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    •• Elliott MA, Dewald GW, Tefferi A, Hanson CA. Chronic neutrophilic leukemia (CNL): a clinical, pathologic and cytogenetic study. Leukemia. 2001;15(1):35–40. Pathologic and cytogenetic features of CNL before molecular profiling of CNL was achieved CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  • Kim-Hien T. Dao
    • 1
    Email author
  • Jeffrey W. Tyner
    • 2
  • Jason Gotlib
    • 3
  1. 1.Knight Cancer Institute, Hematology and Medical OncologyOregon Health & Science UniversityPortlandUSA
  2. 2.Knight Cancer Institute, Department of Cell, Developmental and Cancer BiologyOregon Health and Science UniversityPortlandUSA
  3. 3.Stanford Cancer InstituteStanford UniversityStanfordUSA

Personalised recommendations